We investigated whether two representative 1,4-dihydropyridine derivatives, NK·250 and NK·252, could potentiate the antitumor activity of multiple anticancer agents including vincristine (VCR), vinblastine, vindesine and actinomycin D in drug·resistant tumor cells and their parental drug·sensi· tive tumor cells. NK·250 and NK·252 at 5-10 pM almost completely reversed VCR resistance in cultured VCR·resistant P388IVCR cells derived from the mouse drug·sensitive P388/S leukemia cell line and also potentiated the cytocidal activity of VCR in drug·sensitive P388/S cells. NK·250 and NK·252 at 1-10 pM inhibited the photoaffinity labeling by [3H]azidopine of the cell·surface 170,000. molecular·weight P·glycoprotein. In chemotherapeutic experiments with leukemia·bearing mice, NK· 250 or NK·252 was orally administered in combination with different drugs of the MDR phenotype administered intraperitoneally. The antitumor activity of the various combinations was found to be augmented in mice bearing P388/S· and P388/VCR·leukemia. Among the combinations examined, the combination of NK·250 and VCR was the most effective. These two 1,4·dihydropyridines, NK·250 and NK·252, are unique compounds because they were effective not only in circumventing the drug resistance, but also in potentiating the action of antitumor drugs against drug·sensitive tumors.
Development of simultaneous resistance to multiple anticancer drugs (multidrug-resistance: MDR)4 is a major impediment to the successful chemotherapy of human tumors. I) Expression of an MDR gene (MDR-1) appears to be involved in the appearance of clinical drug resistance. 2 • 3 ) Experimental therapeutic studies to screen MDR-reversing agents have been performed by targeting a membrane 170,OOO-molecular·weight P·glycoprotein (GP170) encoded by the MDR-1 gene. 4 .') Verapamil and other calcium channel blockers can enhance the antitumor activity of Vinca alkaloids and anthracyclines; MDR cells are usually resistant to such antitumor agents.6-IO) Outward transport (efflux) of these MDR· related agents in the MDR cells is mediated by an energydependent drug-efflux pump, GP170.
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tration of these calcium channel blockers, however, causes cardiovascular disorders when their blood concentration is elevated to a level high enough to show the MDR-reversing effect.
One can thus expect potent MDR-reversing agents with reduced calcium channel-blocking activity to be useful for practical cancer chemotherapy. From this standpoint, dihydropyridines with weaker side effects have been searched for to see if they could overcome MDR. Some dihydropyridines have low calcium channelblocking activity, but strong MDR-reversing activity in vivo l2 ) as well as in vitro. 13, 14) In our laboratory, among many dihydropyridines tested, lipophilic l,4-dihydropyridines were found to efficiently overcome MDR in vitro, I') We have further screened 57 newly synthesized 1,4-dihydropyridine derivatives to see whether they could overcome vincristine (VCR) resistance in mice bearing VCR-resistant leukemia. 16) On intraperitoneal (ip) administration trials of such dihydropyridines, some of them with little calcium antagonistic effect or vasodilat· ing activity could strongly potentiate the activity of VCR against drug-resistant leukemia in ViVO, 16) MDR-reversing agents are often screened in vivo by the ip administration of both reversing agent and anti· tumor drug in animals which have been inoculated ip with tumor cells. The reversing agents and antitumor drugs are preferably administered into sites different from that used for inoculation of tumor cells. Other routes besides ip for the administration of the MDRreversing agents should also be considered to develop practical therapeutic methods for clinical use. Our recent in vivo study has demonstrated that two 1,4-dihydropyridines (NK-compounds), NK-250 and NK-252, which have low calcium channel-blocking activity with very high affinity for GP170, can potentiate the activity of VCR in VCR-resistant leukemia-bearing mice when administered ip. 16) In this study, we investigated whether NK-250 and NK-252 could potentiate the effects of VCR, vinblastine (VLB), vindesine (VDS) and actinomycin D (ACD) in P388 leukemia-bearing mice when the dihydropyridine derivatives were orally (po) administered and the antitumor drug was administered ip.
MATERIALS AND METHODS
Cell lines and cell culture The P388 leukemia cell line sensitive to antitumor drugs, P388/S, and its subline, P388/vCR, resistant to VCR, were kindly supplied by Dr. M. Inaba, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research (Tokyo). Cells from P388/S or its resistant subline were grown in suspension in RPMI-1640 medium (Grand Island Biological Co., Grand Island, NY) supplemented with 10% fetal calf serum (Flow Laboratories, Inc., Rockville, MD) in the presence of 10 /-lM 2-hydroxyethyl disulfide (Aldrich Cell growth inhibition assay in vitro Cells from P388/S or its resistant subline, P388/VCR, were harvested from tumor-bearing mice 6 to 7 days after transplantation and were suspended in RPMI-1640 medium with the antitumor agents and/or NK-compounds, seeded at a final density of 5 X 10 4 cells/ml, and incubated in a CO 2 incubator at 37°C for 2 days. Then 4 ml of 0.25% trypsin in calcium, magnesium-free Ringer's buffer solution was added to 1 ml of cell suspension and the mixture was incubated for 5 min at 37°C. The number of cells was counted with a model ZBl Coulter counter. Photoaffinity labeling of P-glycoprotein Membrane vesicles prepared from P388/VCR (120 /-lg of protein/ assay) were incubated with [3H]azidopine (1.5 /-lCi! assay) for 30 min at room temperature with or without NK-compounds and cepharanthine.
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After irradiation for 15 min at 4°C, the samples were solubilized in SDS buffer as described previously.16) Samples of half of the reaction mixture labeled with [3H]azidopine were fractionated by electrophoresis on an SDS-polyacrylamide-urea gel. 16) The gel bed consisted of 5% polyacrylamide/4.5 Murea gel, pH 7.6, without a stacking gel. Evaluation of antitumor activity in vivo CD2F 1 mice were inoculated ip with 0.2 ml of diluted ascites fluid containing 10 6 P388/S or 10 6 P388/vCR cells on day O. Antitumor agents were given ip and NK-compounds were given po once daily for 5 or 10 days starting on day 1. Antitumor activity was evaluated in terms of the mean survival time (in days) for each group and also in terms of the mean survival time of the treated group divided by the mean survival time of the control group (T /C values) (%). The data on mean survival time were analyzed by the two-tailed Student's t test and two-tailed Cochran's t test if the difference in distribution between the two groups to be compared was significant (P< 0.05) by the F test. Antitutmor agents were dissolved in sterilized physiological saline. NK-compounds were suspended in sterilized 0.5% carboxymethyl cellulose sodium salt containing 0.1 % Tween 80 as a vehicle.
RESULTS
Potentiation of VCR by NK-250 and NK-252 against drug-sensitive and drug-resistant cells in culture The drug sensitivity of P388/VCR cells was compared with that of its parental counterpart, P388/S cells, by assaying growth inhibition in vitro as reported by Inaba and Maruyama. 20 ) When the cells were exposed to VCR for 48 h, the 50% growth-inhibiting dose of VCR for P388/ 
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S was about 4 ng/ml, and that for P388/VCR was about 85 ng/m1; P388/VCR was thus 21-fold more resistant to VCR than P388/S (Fig. 2) . The effects of NK-250 and NK-252 combined with various doses of VCR on the growth of P388/S and P388/VCR cells were compared. (Fig. 3) . NK-250 and NK-252 completely inhibited the photoaffinity labeling by eH]azidopine at 10 and 111M, respectively, suggesting specific interaction of the NK-compounds with GPI70 (Fig. 3) . Combined effect of VCR and NK-250 or NK-252 on antitumor activity in P388/S-and P388/VCR-bearing mice Combined effects of VCR and NK-250 or NK-252 on antitumor activity were examined against both P388/ Sand P388/VCR leukemia-bearing mice. Figure 4A illustrates a therapeutic experiment with P388/S-bearing mice given NK-250 at 300 mg/kg po and VCR at 3011g/ kg ip. Figure 4B illustrates a therapeutic experiment with P388/VCR-bearing mice given NK-250 at 300 mg/kg po ..... VCR administered ip once daily for 10 days dosedependently increased the life-span of P388/S leukemiabearing mice (Table I ). The combination therapy of VCR with NK-250 or NK-252 significantly increased the life-span of mice compared with the corresponding effect of VCR alone. The maximum life-prolonging effect (mean survival time of 23.7 days) was observed when P388/S-bearing mice were treated with 100 ,ug/kg VCR and 300 mg/kg NK-252. The combination of VCR at 100 ,ug/kg and a large amount ofNK-250 was toxic (data not shown). VCR administered ip once daily for 10 days starting on day 1 did not increase the life-span of P388/ VCR leukemia-bearing mice (Table II) . The combination therapy of ip administration of VCR with po administration of NK-250 significantly increased the life-span of mice compared with the corresponding effect of VCR alone. This antitumor-enhancing activity of NK-250 was dose-dependent at each dose of VCR. The maximum life-prolonging effect (mean survival time of 16.2 days) was observed when P388/VCR-bearing mice were treated with 100 ,ug/kg VCR and 200 mg/kg NK-250. The combination of VCR at 100 ,ug/kg and a large amount of NK-250 (300 mg/kg) was toxic, and 3 of 6 mice demonstrated toxic signs such as decrease in locomotor activity and body weight loss. The combination therapy of VCR with NK-252 significant increased the life-span of mice, but the prolonging effect was less than with NK-250. No mice were found dead from toxicity with any combination dose of VCR and NK-252. Combined effects of VLB or VDS and NK·250 or NK· 252 on antitumor activity in P388/S· and P388/vCR· bearing mice VLB administered ip once daily for 5 days dose-dependently increased the life-span of P388/S leukemia-bearing mice, with mean survival times of 12.2 and 14.0 days at doses of 30 and 100 ,ug/kg VLB, respectively, but 13.8 days at 200 ,ug/kg VLB (Table  III) . The mean survival times of P388/vCR.bearing mice treated with VLB were 9.2, 12.0 and 12.7 days at 30, 100 and 200 ,ug/kg of VLB, respectively, suggesting weak cross-resistance of P388/VCR to VLB in vivo. The combination of VLB (ip) and NK-250 or NK-252 (po) significantly increased the life-span of P388/S-and P388/VCR-bearing mice compared with VLB alone (Table III) . The maximum mean survival was 20.2 and 16.7 days, respectively, when P388/S-and P388/VCRbearing mice were treated with 200 ,ug/kg VLB and 200 mg/kg NK-250. The prolonging effect of NK-252 on the survival time was less than that of NK-250.
VDS administered ip once daily for 5 days dosedependently increased the life-span of P388/S leukemiabearing mice, with mean survival tines of 11.0, 12.8 and 14.3 days at doses of 10, 30 and 100 ,ug/kg VDS, respectively (Table III) . The mean survival times of P388/ VCR-bearing mice were 10.3, 10.0 and 9.8 days when Male CD2F 1 mice were inoculated ip with 10 6 cells of P388/S or P388/VCR cell line on day O. ACD (ip) and NK-compounds (po) were given once daily from day 1 to·day 5. The control group consisted of 12 to 18 mice, the ACD alone group consisted of 6 to 12 mice and the groups treated with ACD and NK-compounds consisted of 5 or 6 mice. Asterisks indicate a significant difference from the respective result with the same dose of ACD alone by Student's and Cochran's t tests: * P< 0.05, * * P< 0.01, * ** P< 0.001. they were treated with 10, 30 and 100,ug/kg of VDS, respectively, suggesting cross-resistance of P388/VCR to VDS in vivo. The combination of VDS (ip) and NK-250 or NK-252 (po) significantly increased the life-span of P388/S-and P388/VCR-bearing mice compared with VDS alone. When P388/S-bearing mice were treated with 100 ,uglkg VDS and 300 mg/kg NK-250, and P388/ VCR-bearing mice were treated with 1oo,ug/kg VDS and 200 mg/kg NK-250, the maximum mean survival times were 20.7 and 16.0 days, respectively. The effect of NK· 252 was, however, less than that of NK·250. In the combination of 100 ,ug/kg VDS and 300 mglkg NK·250, 3 of 6, and in the combination of 100 ,uglkg VDS with 300 mglkg NK·252, 1 of 6 P388/VCR-bearing mice died from toxicity on days 5 to 7 and on day 7, respectively. Combined effect of ACD and NK·250 or NK·252 on antitumor activity in P388/S· and P388/VCR·bearing mice ACD administered ip once daily for 5 days dosedependently increased the life-span of P388/S leukemiabearing mice (Table IV) . The mean survival times for P388/VCR-bearing mice treated with 10, 25 and 50,ug/ kg ACD were 11.6, 12.8 and 13.4 days, suggesting rather weak cross-resistance of P388/VCR-bearing mice to ACD. The combination of ACD (ip) and NK-250 or NK·252 (po) significantly increased the life-span of P388/S-and P388/VCR-bearing mice compared with ACD alone (Table IV) . When P388/VCR-bearing mice 1062 were treated with 50 ,uglkg ACD and 300 mg/kg NK-250, the maximum life-prolonging effect, a mean survival time of 18.2 days, was observed. No mice were found dead from toxicity at any combination of doses of ACD with NK-250 and NK-252.
DISCUSSION
Resistance to antitumor drugs can be overcome in vivo by various agents including verapamil,16) isoprenoid 21 ) and vitamin A 22 ) when these reversing agents are administered ip. The potentiation effects of these agents when combined with antitumor drugs have not yet been verified in practical cancer chemotherapy. Some 1,4-dihydropyridine derivatives can reverse MDR in cultured human cancer cell lines through interaction with GP170, resulting in increased accumulation of the antitumor drugs in drug-resistant cells. I~) Several of our newly synthesized l,4-dihydropyridine derivatives have been further screened by determination of three different activities: in vivo VCR resistance-reversing activity in mice, affinity to GP170 and in vitro calcium antagonistic activity or in vivo hypotensive activity.16) Six of the 57 dihydropyridine derivatives can potently reverse VCR resistance in leukemia-bearing mice, and 4 among the 6 compounds have much lower calcium-antagonistic and hypotensive activities than verapamil or nicardipine. AHC-52, with less calcium-antagonizing activity than nifedipine, shows some structural similarity to NK-250 or NK-252, but in AHC-52 some of the 3,4,5-substituents of l,4-dihydropyridine are completely different from those of NK-250 or NK-252. These independent studies of l,4-dihydropyridine derivatives might reveal potent MDR-reversing agents with fewer side effects which could be suitable for practical use. In our present study, we demonstrate that NK-250 and NK-252 can overcome VCR resistance in an MDR cell line, P388/VCR, in culture (Fig. 2) . Our previous study showed a more than 130% (T IV) increase in the life-span of P388/VCRbearing mice when NK-250 and NK-252 were administered ip.16) In this study, NK-250 or NK-252 was administered by the oral route. Combinations of ip administration of the antitumor drugs, VCR, VLB, VDS and ACD, and oral administration of NK-250 or NK-252 significantly enhanced the antitumor activity in P388/VCR-bearing mice (Tables I-IV) , but only a slight (if any) effect appeared when adriamycin (ADM) was combined with the NK-compounds (unpublished data). NK-250 and NK-252 significantly potentiated VCR, ACD, VLB and VDS in P388/S-bearing mice (Tables 1-IV) , but not ADM (unpublished data).
Most agents that reverse MDR, such as cepharanthine, verapamil, reserpine and isoprenoids, inhibit the efflux pump activity which is mediated by cell-surface GP 170 and the photoaffinity labeling of GP170 by (Fig. 3) . MDR-related antitumor drugs are expected to show high affinity to GP-170, S, 17. 19,23-25) but the specific affinity to GP 170 of P388/ VCR appears to differ among the antitumor drugs. Different affinity constants among the antitumor drugs for GP170 may affect the potentiation by NK-250 or NK-252 of the MDR-related antitumor drugs in P388/ VCR-bearing mice. Other possibilities such as differences in drug metabolism and sites of action of the antitumor drugs, may also be involved in the dissimilar potentiation by NK-compounds.
NK-250 and NK-252 potentiated VCR, VLB, VDS and ACD in drug-sensitive P388/S leukemia-bearing mice in vivo as well as VCR in P388/S cells in vitro. However, drug-sensitive P388/S (this study) and KBI6, 26) cells show no significant expression of GP170. Our recent study demonstrated significantly enhanced accumulation of radioactive VCR in both drug-sensitive cells and their MDR counterpart cells.27l However, the precise mechanism of the increase in antitumor activity of VCR or other antitumor drugs by the dihydropyridines in P388/S-bearing mice is not yet known. From our present study and the previous one l6 ) we consider that dihydropyridines such as NK-250 and NK-252 are unique agents in their ability to potentiate antitumor agents in drug-sensitive and drug-resistant tumors in vivo when administered ip and po. Further studies on the toxicology, pharmacology and drug metabolism of NK-250 and NK-252 are required before they can be put to clinical use. 
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